Some possible reasons are higher frequency of preexisting comorbidities, more present high-risk behavior related to COVID-19, differences in innate immune response, and different activity and expression of angiotensin-converting enzyme 2 (ACE 2) [26,27]. This evidence concerns the gene ACE2 and COVID-19.